Yahoo Finance Did Changing Sentiment Drive Khiron Life Sciences's (CVE:KHRN) Share Price Down A Painful 87%?
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid truly shocking capital losses. It must have been painful to be a Khiron Life Sciences Corp. (CVE:KHRN) shareholder over the last year, since the stock price plummeted 87% in that time. That'd be enough to make even the strongest stomachs churn. We wouldn't rush to judgement on Khiron Life Sciences because we don't have a long term history to look at. Furthermore, it's down 46% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 27% decline in the broader market, throughout the period.
We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.
Check out our latest analysis for Khiron Life Sciences
Given that Khiron Life Sciences didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Khiron Life Sciences stock, you should check out this free report showing analyst profit forecasts.
A Different Perspective
Khiron Life Sciences shareholders are down 87% for the year, even worse than the market loss of 24%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. With the stock down 46% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Given the relatively short history of this stock, we'd remain pretty wary until we see some strong business performance. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 4 warning signs for Khiron Life Sciences (of which 1 is significant!) you should know about.
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CA exchanges.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
